ElectroCore Q3 2026 net loss narrows 61% to $1.34 million; sales rise 12% to $9.69 million
ECOR•ElectroCore’s third-quarter 2026 net loss narrowed 61% to $1.34 million, while net sales rose 12% to $9.69 million. It revised full-year revenue guidance to $39 million–$42 million and issued preliminary 2027 growth guidance of 30%–40%.
1. Quarterly results
ElectroCore reported a third-quarter 2026 net loss of $1.34 million, down 61% year over year, and revenue of $9.7 million, up 12%. Sales of Quell Fibromyalgia and prescription gammaCore through the VA primarily drove the revenue increase.
2. Outlook and FDA filing
The company revised its 2026 revenue outlook to $39 million–$42 million, replacing its previous expectation for growth above 30%. Preliminary 2027 guidance calls for revenue growth of 30%–40% over 2026. In October, electroCore submitted an FDA application seeking clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy.
